AG
AGRX

Advisor Group’s Agile Therapeutics AGRX Stock Holding History

Advisor Group’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$368K Hold
74
– – ﹤0.01% 1898
2019
Q3 		$174K Hold
74
– – ﹤0.01% 2429
2019
Q2 		$215K Hold
74
– – ﹤0.01% 2256
2019
Q1 		$222K Buy
74
+65
+722% +$138K ﹤0.01% 2207
2018
Q4 		$10K Hold
9
– – ﹤0.01% 4221
2018
Q3 		$7K Buy
+9
New +$6.59K ﹤0.01% 4472

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Advisor Group's AGRX Position: Q4 2019 in Review

Advisor Group held its Agile Therapeutics (AGRX) position steady in Q4 2019 at 74 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #1898.

Advisor Group first reported a position in AGRX in Q3 2018 and has held it in 6 quarters since. 46 funds tracked by Wall St. Rank hold AGRX as of Q4 2019.

  • Advisor Group held 74 shares of Agile Therapeutics worth $368K as of Q4 2019.
  • Advisor Group left its Agile Therapeutics share count unchanged in Q4 2019.
  • Agile Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #1898 holding.
  • Advisor Group first reported a position in Agile Therapeutics in Q3 2018 and has held it in 6 quarters since.
  • 46 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.